Business Wire

Six Planview Spigit Customers Recognized for Exemplary Crowdsourced Innovation Programs That Inspire Employee Engagement, Creativity, and Excellence

Share

Ignite – the Innovation Summit powered by Planview – brought together transformational leaders and practitioners from some of the world’s leading companies to share their perspectives and expertise on delivering value through strategic innovation. Held in Atlanta, New York City, San Francisco, and London, the 2019 summits also recognized Planview Spigit customers Starbucks, Johnson & Johnson, CGI, EDF Energy, and Highmark Health for achieving significant advancements in their crowdsourced innovation journeys.

“Bringing our customers together at Ignite is always an exhilarating experience. It was tremendously inspiring to witness and celebrate the profound impact these market leaders are having on transforming their businesses,” said Virginia Lee Williams, Planview vice president, global innovation management solutions. “The six Planview Spigit customers honored with 2019 Ignite innovation awards are truly on the cutting edge of developing and advancing programs that inspire employee engagement, creativity, and excellence.”

“Planview Spigit has been a game changer for CGI,” said Megan Bishop, ICE (Innovate, Collaborate, Evolve) program manager at CGI. “We have a rich tradition of offering our consultants and professionals the opportunity to initiate and champion creative ideas. This innovation management platform has expanded and accelerated our ability to bring more ideas to life across all of our geographies to deliver immediate value to our clients.”

CGI – Most Innovative Use Case Award

Founded in 1976, CGI is among the largest independent IT and business consulting services firms in the world with approximately 77,500 consultants and professionals. CGI leverages Planview Spigit to generate and advance new ideas through expansive crowdsourcing with continual challenges that scale enterprise-wide collaboration and value.

Starbucks – New Innovation Program of the Year Award

In just under one year, Starbucks ran over 30 challenges in Planview Spigit across the organization through its newly created innovation hub. The outcome has been a notable increase in sourcing and implementing breakthrough initiatives that are driving better in-store experiences, innovating its beverage platform, and creating stronger digital relationships: www.cnbc.com/2019/05/02/starbucks-is-speeding-up-innovation-at-its-seattle-research-hub.html.

Highmark Health – New Innovation Program of the Year Award

As a national health and wellness organization of more than 43,000 employees, Highmark Health is inspired by a bold mission to create a remarkable health experience, freeing people to be their best. Having just implemented Planview Spigit in December 2018, Highmark Health had a 67 percent engagement rate among employees invited to participate in idea submission that spurs innovation and has been able to sustain that employee interaction in subsequent campaigns.

Johnson & Johnson – Best Employee Engagement Award

Within just 30 days, Johnson & Johnson ran 29 simultaneous Planview Spigit challenges in more than 10 languages, resulting in 30,000 employee-inspired actions and submissions. The J&J innovation program includes over 16,000 highly engaged and active participants across multiple countries, led by business unit champions who provide localized autonomy and coordination for advancing new ideas.

EDF Energy – Winning Idea of the Year Award

EDF Energy is the UK’s largest producer of low-carbon electricity. The company’s innovation accelerator, Blue Lab, uses Planview Spigit to power idea generation and wider business transformation. Launching both tactical and strategic campaigns in Planview Spigit generated lifesaving safety solutions and the winning idea of the year with ”Skip a Trip,” designed to enhance employee wellbeing and produce savings on travel costs.

Cambia Health Solutions – Innovation Excellence Award

Headquartered in Portland, Oregon, Cambia is a family of over 20 companies that work together to make the health care system more person-focused and economically sustainable for people and their families. Through its “Innovation Force” (IF) team, Cambia has engaged over 70 percent of its employees through signature programs such as PitchWELL – a collaboration between Cambia’s Women’s Employee Leadership Lab and IF to advance idea development as a new format for professional mentoring.

The award recognizes Cambia’s approach to impacting culture through ideas and its continuous drive to grow and mature the program, with more than 2,500 ideas generated and four internally built companies.

“Our commitment to fuel growth through employee engagement and idea creation across our entire family of companies has continued to deliver strong results,” said Mohan Nair, chief innovation officer at Cambia Health Solutions. “While many companies approach innovation as a discrete program or initiative, Cambia treats innovation as a value – engaging employees, surfacing passions, and prioritizing people over ideas for health care innovation.”

About Planview Spigit

More than 500 companies across 170 countries spanning every industry use Planview Spigit to drive continuous innovation, fuel employee engagement, create a culture of innovation, and provide analytics driven insights across the enterprise.

Assess your innovation program and how to achieve more success with the Planview Spigit benchmark tool: www.spigit.com/innovation-program-benchmark-tool/.

About Planview

There is a bold new way of working, where every individual and team can move seamlessly from strategy to successful delivery – every day. Planview makes it possible. We empower you with a single line of sight across your entire organization and help every team collaborate to create value. Imagine realizing Agile at scale, creating a culture of innovation, and making the product shift. You are a change agent. So are we. For more information, visit www.planview.com.

Planview, Planview Spigit, and Planview Horizons are registered trademarks of Planview, Inc.

All other trademarks listed herein are owned by their respective companies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Planview
Karoline McLaughlin
kmclaughlin@planview.com
+1 512 596 3493

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release

Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla

Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release

Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log

TOM FORD Unveils Black Orchid Reserve Campaign Starring Tilda Swinton29.8.2025 07:35:00 EEST | Press release

The quest for exceptional rarity. Introducing Tilda Swinton for the new TOM FORD Black Orchid Reserve campaign. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828507187/en/ “It is a profound honour for me to play a part in the history of TOM FORD’s legendary Black Orchid. Transformation, the blurring of boundaries and the celebration of magical properties have always drawn me close; Black Orchid Reserve is precisely such an enchantment.” — Tilda Swinton A celebrated actor and artist, Swinton is a singular presence known for her fearless artistry and transformative performances. An Academy Award, BAFTA and Golden Lion for Lifetime Achievement winner, Swinton defies conventions with elegance, intellect and a visionary approach to cinema. Her work transcends definition, shaping the culture through work in film, art and performance. TOM FORD creative director Haider Ackermann designed the campaign as a cinematic portrait of r

Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma28.8.2025 23:15:00 EEST | Press release

Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ Pharma) in achieving a significant regulatory milestone: the approval of Anlotinib Hydrochloride Capsules for a new indication as a first-line treatment for unresectable locally advanced or metastatic soft tissue sarcoma (STS) in combination with chemotherapy. This approval marks the ninth indication for Anlotinib in China and represents the world’s first official approval of an Anlotinib-chemotherapy combination for first-line treatment of advanced or metastatic STS. Previously recommended as a second-line monotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines, Anlotinib was the only Grade I targeted therapy for STS. This new indication represents a significant advancement for patients who have not previously received systemic treatment, expanding access to more effective and targeted first-line the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye